Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06311981
Status:
RECRUITING
Last Update Posted:
2024-03-15
First Post:
2024-03-09
Brief Title:
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
Sponsor:
Jian Chen
Organization:
Shanghai Proton and Heavy Ion Center
Study Overview
Official Title:
A Prospective Phase II Clinical Study of Carbon Ion Radiotherapy for Locally Advanced Non-small Cell Lung Cancer in the Older Adult
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients Systemic therapy could be targeted therapy chemotherapy or immunotherapy
Detailed Description:
The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions Patients with genetic mutations including but not limited to EGFR ALK etc should receive targeted therapy as their systemic therapy For patients who are not suitable for targeted therapy we recommend single regimen chemotherapy in sequence with radiotherapy The drugs include etoposide platinum carboplatin cisplatin nedaplatin or loplatin vinorelbine paclitaxel including liposome paclitaxel and albumin paclitaxel docetaxel pemetrexel gemcitabine etc If there is no contraindication to PD-1PD-L1 immunotherapy it can be combined with immunotherapy such as Pembrolizumab For patients who cannot tolerate chemotherapy PD-1PD-L1 immunotherapy is recommended The progression-free survival rate toxicity local control rate cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None